First Week of CGON February 2026 Options Trading

The note outlines two option strategies for CG Oncology (CGON) around the current share price of $38.77: selling a $35 put (bid $0.30) which sets an effective purchase basis of $34.70 and is ~10% out‑of‑the‑money with a 68% probability of expiring worthless, producing a 0.86% return (4.97% annualized) if it does. The covered‑call example sells the $40 call (bid $1.50) against shares bought at $38.77, yielding 7.04% total return if called at the Feb‑2026 expiry and a 3.87% premium boost (22.42% annualized) if the call expires worthless; implied vols are ~68–69% vs. 12‑month realized volatility of 66%.

Analysis

Market structure: The immediate winners are option premium sellers (income strategies) because IV (68–69%) slightly exceeds realized vol (66%), making short-dated premium structurally attractive for ~60–90 day expiries; downside losers are long-only holders if a binary biotech event triggers a >30% gap. Competitive dynamics: CGON remains idiosyncratic—moves will reallocate small-cap biotech weightings (XBI-style ETFs) rather than change large-cap market structure, so relative-value flows will matter more than systematic flows. Supply/demand: Option supply (retail/corporate income demand) is likely to stay available at these IVs; however limited free float and low institutional depth amplify price moves on gamma events. Cross-asset: A major adverse trial/regulatory surprise would increase cross-asset volatility (push VIX and small-cap put demand), raise correlation with high-yield credit spreads for speculative biotechs, and slightly depress risk-on FX/commodity beta for the sector over 48–72 hours.

Risk assessment: Tail risks are classic biotech binaries—trial failure, FDA reject, or urgent dilutive financing—each could cut equity value >50% and spike IV >150% in 24–72 hours. Time horizons matter: in days trade P/L dominated by gamma; in 1–3 months catalysts (trial updates, cash burns) set direction; beyond 6–12 months funding/dilution and clinical readouts determine valuation. Hidden dependencies: runway, milestone payments, or a partnering term sheet can suddenly re-rate IV and shares; capital raises are the highest second-order dilution risk. Catalysts to watch: announced data readouts, 10-Q cash runway disclosures, and any partnership or IND updates in the next 30–90 days.

Trade implications: Direct plays—sell-to-open $35 puts (collect $0.30; 0.86% yield over cash commitment, ~4.97% annualized) if willing to own at $34.70, with position sizing 1–2% portfolio and reserve cash = $35×contracts. Covered-call play—buy 100 CGON at $38.77 then sell $40 Feb 2026 calls to lock 7.04% to expiry (50% chance to expire worthless per current analytics); use collars if worried about >25% downside. Options strategies: prefer defined-risk credit spreads (sell $35/$30 put spreads) to limit tail risk while harvesting premium; consider buying calls only ahead of confirmed positive catalysts when IV is rising. Sector rotation: trim non-core small-cap biotech exposure by 1–3% and reallocate to diversified big-cap pharma or defensive healthcare until next clinical-readout window closes.

Contrarian angles: Consensus income bias (selling premium) underestimates dilution risk—being assigned at $35 then facing a financing at a materially lower price is the biggest overlooked loss vector. The IV ~2–3 pts above realized suggests the premium is fair, not rich—shorting volatility is OK sized but not naked for more than 1–2% portfolio. Historical parallels: small-cap biotechs often see 40–70% binary moves around readouts; unlike broader selloffs, recovery can be gradual over quarters, not days. Unintended consequence: systematic selling of premium by retail could concentrate short-gamma exposure into quarters of imminent readouts—if multiple pins occur, forced deleveraging could exacerbate downside beyond modelled probabilities.

Key Decisions for Investors

• Sell-to-open CGON Feb 2026 $35 puts (collect ~$0.30) sized to 1–2% portfolio risk (max cash reserve $35×contracts); plan to accept assignment at $34.70 but buy-to-close if CGON < $33 or IV expands >90% (close if premium rises >100%).
• If bullish on share ownership, buy 100 CGON at ~$38.77 then sell Feb 2026 $40 covered calls (collect ~$1.50) to lock ~7.04% return to expiry; set buy-to-close target if stock > $42 (protect realized upside) or if combined position loss >10%.
• Use defined-risk credit spreads instead of naked puts: sell Feb 2026 $35 put and buy $30 put (bull put spread) to cap downside; target 40–60% of max profit as a take-profit trigger and close at 50% of premium remaining.
• Monitor catalysts and disclosures over next 30–90 days: if 10-Q shows cash runway <12 months or a negative trial update occurs, reduce CGON exposure by 50% and unwind short premium positions immediately to avoid forced assignment/dilution losses.